Q1 was strong, led by third consecutive quarter of acceleration in sales in the Bioscience division and the return to growth of the Bio supplies division. While the Diagnostics division slipped into the red due to lockdowns across key geographies, the business should be back on track once Grifol’s COVID-19 tests hits the market. Approval (expected in July) of convalescent plasma for the treatment of COVID-19 could be a game-changer for Grifols, and the overall plasma industry.
22 Apr 2020
Robust Q1 results; COVID-19 treatment could be a game-changer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Robust Q1 results; COVID-19 treatment could be a game-changer
Grifols, S.A. Class A (GRF:WBO) | 0 0 1.0% | Mkt Cap: 14,874m
- Published:
22 Apr 2020 -
Author:
Rishabh Kochar -
Pages:
3
Q1 was strong, led by third consecutive quarter of acceleration in sales in the Bioscience division and the return to growth of the Bio supplies division. While the Diagnostics division slipped into the red due to lockdowns across key geographies, the business should be back on track once Grifol’s COVID-19 tests hits the market. Approval (expected in July) of convalescent plasma for the treatment of COVID-19 could be a game-changer for Grifols, and the overall plasma industry.